

## Bulletin from the extraordinary general meeting of INIFY Laboratories AB

Today, December 4, 2025, an extraordinary general meeting was held in INIFY Laboratories AB, reg. no. 559345-4431 (the "Company"). At the meeting, 66,655,976 shares were represented, corresponding to 84.5 per cent of the total number of shares and votes in the Company. Below follows a summary of the resolution adopted at the meeting.

### Resolution on directed share issues

The general meeting resolved, in accordance with the board of directors' proposal, on a directed issue of shares to SB1 Markets AS for onward transfer to major shareholders in the Company (the "**Private Placement**") and on a directed issue of shares to SB1 Markets AS for onward transfer to other shareholders in the Company (the "**Repair Issue**"). Details and timetable for the Private Placement and the Repair Issue are set out in the Company's press releases dated November 12, 2025 and December 3, 2025, respectively.

### For further information, contact:

Ann-Charlotte Linderöth, CFO

E-mail: [ann-charlotte.linderöth@inify.com](mailto:ann-charlotte.linderöth@inify.com)

###

*This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.*

###

### The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis – using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Solna, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on [Euronext Growth Oslo](#) under the ticker [INIFY](#).